The FDA (Food and Drug Administration) has given the green light to human clinical trials for gene therapy developed by the fellow Silvia G. Priori and her team.
The therapy is aimed at the treatment of a serious arrhythmogenic pathology of genetic origin for which, to date, there are no targeted treatments called ventricular tachycardia polymorph catecholaminergic